Bipolar androgen therapy (BAT) resulted in similar progression-free survival and reduction in prostate-specific antigen (PSA) compared with enzalutamide among men with metastatic castration-resistant prostate cancer

https://journals.lww.com/fpmrs/Abstract/2021/02000/Recurrent_Urinary_Tract_Infection_in_Women_.10.aspx?context=LatestArticles